Skip to content
Bamboo Works
Search
Register / Sign in
MSCI China | MSCI China Small-Cap | Hang Seng Index | Hang Seng China Enterprise
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us
  • Eng
  • 简中
  • 繁中
Menu
  • Categories
    • IPO
    • Ecommerce
    • Finance
    • Social Media/Entertainment
    • Consumer
    • Education
    • Healthcare/biotech
    • New Energy
    • AI/Infrastructure/Resources
    • Property
  • Fast News
  • Expert Corner
  • Audio/Video
  • China ESG
  • About
    • Who We Are
    • Our Writers
    • Partner with us
    • Contact Us
    • Join us

biopharma

Clover Biopharmaceuticals Ltd. faces a potentially damaging fight

Dispute over Covid vaccines casts doubt on Clover Bio recovery

The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
April 3, 2025
2197.HK
BeiGene

BeiGene heads for profit milestone after hemorrhaging cash

With a blockbuster drug under its belt and another product approved for U.S. sale, the biopharma firm says it is on track to post an annual operating profit this year…
January 24, 2025
6160.HK ONC.US 688235.SHG

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat

Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list…
May 6, 2022

Recent Articles

Clover Biopharmaceuticals Ltd. faces a potentially damaging fight
April 3, 2025

Dispute over Covid vaccines casts doubt on Clover Bio recovery

2197.HK
January 24, 2025

BeiGene heads for profit milestone after hemorrhaging cash

6160.HK ONC.US 688235.SHG
May 6, 2022

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat

RELATED ARTICLES

  1. Zhengye completes IPO, but more likely to come
    January 20, 2025
    Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
    ZYBT.US
  2. March 25, 2025
    Everest Medicines drives growth with AI-powered mRNA pipeline
    1952.HK
  3. January 16, 2025
    WuXi Biologics sells vaccine plant as new U.S. law looms
    2269.HK
  4. March 25, 2025
    NEWS WRAP: Lianlian DigiTech’s revenue surges on payment network expansion
    2598.HK
  5. February 21, 2025
    As Covid drug cash dwindles, Vigonvita targets new remedies
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

China stock insights and analysis for global investors: Bamboo Works unlocks investment opportunities in Chinese companies listed in the U.S. & Hong Kong.

  • About Us
  • Fast News
  • Audio/Video
  • Expert Corner
  • China ESG
Facebook Twitter Linkedin Weixin Weibo Youtube

Categories

  • New Energy
  • IPO
  • AI/Infrastructure/Resources
  • Education
  • Finance
  • Social Media/Entertainment
  • Consumer
  • Ecommerce
  • Healthcare/biotech
  • Property

Newsletter

Discover hidden China stock gems in our weekly newsletter
Copyright © 2021 - 2025 Bamboo Works. All rights reserved.